Clinical Scorecard: Enhancing Access to Lung Cancer Screening with Emphasis on Health Disparities: Insights from Professionals in the UK NHS Lung Cancer Screening Initiative

At a Glance

Key Highlights

• Lung cancer is the leading cause of cancer death globally, with smoking responsible for approximately 85% of cases.
• LDCT screening reduces lung cancer mortality by 20–24%, but uptake remains low (20.4%–52.6%) compared to other cancer screenings.
• Significant social, ethnic, and health inequalities affect lung cancer incidence and screening uptake, with lower participation in socioeconomically deprived groups and current smokers.

Guideline-Based Recommendations

Diagnosis

• Use LDCT scanning for early detection in eligible high-risk individuals based on age, smoking history, and risk models (PLCOm2012, LLPv2).
• Exclude individuals exceeding scanner weight/size limits, unable to lie flat, or with poor physical fitness contraindicating curative treatment.

Management

• Implement targeted invitation strategies focusing on high-risk populations in areas of high smoking prevalence and deprivation.
• Ensure screening accessibility and equity by addressing barriers such as fear, fatalism, mistrust, and structural inequalities.

Monitoring & Follow-up

• Monitor screening uptake rates across demographic groups to identify and address disparities.
• Evaluate effectiveness of invitation and engagement strategies to improve participation.

Risks

• Recognize that individuals with comorbidities or disabilities may have lower screening uptake despite eligibility.
• Consider physical and logistical limitations that may exclude some high-risk individuals from screening.

Patient & Prescribing Data

Screening-eligible individuals aged 55-74 with smoking history and high lung cancer risk

Screening uptake is lower in socioeconomically deprived groups and current smokers despite higher lung cancer risk; addressing barriers is essential to improve participation.

Clinical Best Practices

• Adopt inclusive invitation strategies that consider socioeconomic and ethnic disparities to enhance equitable access.
• Engage healthcare professionals and community stakeholders to build trust and reduce fear and fatalism around lung cancer screening.
• Continuously assess and adapt screening protocols to address physical and logistical barriers for eligible individuals.

References

• UK NHS Lung Cancer Screening Programme
• International Lung Cancer Screening Trials
• UK National Screening Committee Lung Cancer Screening Guidance